close

SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases. The company focus on products for use in defense against biological warfare agents, such as smallpox, arenaviruses (hemorrhagic fevers), and other category A viral agents. Its lead product, ST-246, is an orally administered anti-viral drug that targets orthopox viruses. The company's product candidates also include ST-294 and ST-193, which demonstrates antiviral activity in cell culture assays against arenavirus pathogens; and ST-669, a broad spectrum antiviral candidate, for various viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. In addition, it also has four drug series in the pre-clinical development stage, including ST-610 and ST-148 for dengue virus of the genus Flavivirus. The company has license agreements, collaborative research arrangements, and contracts with National Institutes of Health and the United States Air Force. SIGA Technologies was founded in 1995 and is headquartered in New York, New York.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	2.80
Volume	392822
Volume Avg	514802
52 Week High	15.40
52 Week Low	1.78
PE	33.60
PE (group average)	39
EPS Year	0.09
EPS change Q/Q	-67.86%
EPS change Q/Q Yr ago	-18.18%
EPS change Q/Q next Q est	-25%
EPS change Y/Y	-28.81%
REV change Q/Q	-45.16%
REV change Q/Q Yr ago	-66.67%
EPS next Q est	-0.12
EPS next Y est	-0.20
Divident Annual	0.00
Dividend Yield	0%